A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease

Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury

(2015) Sandy R. Shultz et al.   BRAIN

Methodological considerations on tract-based spatial statistics (TBSS)

(2014) Michael Bach et al.   NEUROIMAGE

Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models

(2011) Nigel C. Jones et al.   NEUROBIOLOGY OF DISEASE

Avoiding asymmetry-induced bias in longitudinal image processing

(2011) Martin Reuter et al.   NEUROIMAGE

FSL

(2011) Mark Jenkinson et al.   NEUROIMAGE

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

(2010) N M Corcoran et al.   BRITISH JOURNAL OF CANCER

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

(2010) J. van Eersel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

(2009) Susan M. Landau et al.   NEUROBIOLOGY OF AGING

Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease

(2008) C.-X. Gong et al.   CURRENT MEDICINAL CHEMISTRY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference

(2008) S SMITH et al.   NEUROIMAGE